Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06455449




Registration number
NCT06455449
Ethics application status
Date submitted
28/09/2023
Date registered
12/06/2024
Date last updated
8/11/2024

Titles & IDs
Public title
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Scientific title
A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Secondary ID [1] 0 0
D3463C00003
Universal Trial Number (UTN)
Trial acronym
JASMINE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Polymyositis, Dermatomyositis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Neurological 0 0 0 0
Other neurological disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Anifrolumab (blinded)
Other interventions - Placebo
Other interventions - Anifrolumab (unblinded, open label)

Experimental: Anifrolumab (subcutaneous weekly injection) - Anifrolumab subcutaneous injection once weekly

Placebo comparator: Placebo (subcutaneous weekly injection) - Matched placebo control subcutaneous injection once weekly


Other interventions: Anifrolumab (blinded)
Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks

Other interventions: Placebo
Matched placebo delivered subcutaneously, once weekly for 52 weeks

Other interventions: Anifrolumab (unblinded, open label)
At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Total Improvement Score (TIS) = 40 response
Timepoint [1] 0 0
52 week
Secondary outcome [1] 0 0
Manual Muscle Testing 8 (MMT-8)
Timepoint [1] 0 0
52 week
Secondary outcome [2] 0 0
Oral corticosteroid dose = 7.5 mg/day
Timepoint [2] 0 0
52 week
Secondary outcome [3] 0 0
Moderate improvement in disease activity in participants with polymyositis (PM)
Timepoint [3] 0 0
52 week
Secondary outcome [4] 0 0
Moderate improvement in disease activity in dermatomyositis (DM) participants.
Timepoint [4] 0 0
52 week
Secondary outcome [5] 0 0
Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Timepoint [5] 0 0
8 week
Secondary outcome [6] 0 0
Core Set Measures (CSMs)
Timepoint [6] 0 0
52 week
Secondary outcome [7] 0 0
Cutaneous Dermatomyositis Activity Investigator Global Assessment (CDA-IGA)
Timepoint [7] 0 0
8, 24, & 52 week
Secondary outcome [8] 0 0
5-D itch
Timepoint [8] 0 0
8, 24, & 52 week
Secondary outcome [9] 0 0
Total Improvement Score (TIS) = 20 Response
Timepoint [9] 0 0
8 week
Secondary outcome [10] 0 0
Cumulative Corticosteroid Use
Timepoint [10] 0 0
24, 52 week
Secondary outcome [11] 0 0
TIS = 60 Response
Timepoint [11] 0 0
52 week

Eligibility
Key inclusion criteria
Capable of giving informed consent.



1. 18 - 75 years old
2. Body weight 40 kg - = 100 kg
3. Must have "probable" or "definite" diagnosis of PM or DM according to the 2017 ACR/EULAR classification criteria for adult myositis.
4. Moderate or severe disease activity per core set measurements.
5. Currently receiving oral prednisone or other polymyositis or dermatomyositis treatments at a stable dose.
6. No history of active tuberculosis or severe COVID-19.
7. Male and female participants must follow contraception guidelines.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants with documented inclusion body myositis (IBM), immune mediation necrotizing myositis (IMNM), juvenile myositis (if diagnosed within 10 years prior to signing the ICF), drug-induced myositis, cancer associated myositis, amyopathic DM, and non inflammatory myopathies (eg, muscular dystrophies).
2. PM and DM patients at a high risk of malignancy.
3. Participants with rapidly progressive interstitial lung disease.
4. Participants with severe muscle damage or permanent weakness due to non-PM or non-DM conditions (i.e. stroke) as per the investigator's opinion.
5. Any history of severe case of herpes zoster infection
6. History of cancer (except adequately treated basal cell carcinoma or cervical cancer in-situ), immunodeficiency, HIV, HBV, active HCV .
7. Any clinical cytomegalovirus or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF.
8. Opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years prior to randomization.
9. Recent non-opportunistic infection requiring hospitalization or anti-infective treatment.
10. Recent or concurrent enrollment in another clinical study with an investigational product.
11. Lactating, breastfeeding, or pregnant females or females who intend to become pregnant or begin breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/06/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
4/08/2028
Actual
Sample size
Target
240
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Nedlands
Recruitment hospital [3] 0 0
Research Site - New Lambton
Recruitment hospital [4] 0 0
Research Site - Woodville South
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment postcode(s) [3] 0 0
2310 - New Lambton
Recruitment postcode(s) [4] 0 0
5011 - Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
United States of America
State/province [10] 0 0
Wisconsin
Country [11] 0 0
Austria
State/province [11] 0 0
Graz
Country [12] 0 0
Belgium
State/province [12] 0 0
Gent
Country [13] 0 0
Belgium
State/province [13] 0 0
Leuven
Country [14] 0 0
Belgium
State/province [14] 0 0
Merksem
Country [15] 0 0
Brazil
State/province [15] 0 0
Joinville
Country [16] 0 0
Brazil
State/province [16] 0 0
Juiz de Fora
Country [17] 0 0
Brazil
State/province [17] 0 0
Pelotas
Country [18] 0 0
Brazil
State/province [18] 0 0
Porto Alegre
Country [19] 0 0
Brazil
State/province [19] 0 0
Salvador
Country [20] 0 0
Brazil
State/province [20] 0 0
Sao Jose Do Rio Preto
Country [21] 0 0
Brazil
State/province [21] 0 0
Sao Paulo
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Haskovo
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Plovdiv
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sofia
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Stara Zagora
Country [26] 0 0
Canada
State/province [26] 0 0
Alberta
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Chongqing
Country [30] 0 0
China
State/province [30] 0 0
Dongguan
Country [31] 0 0
China
State/province [31] 0 0
Guangzhou
Country [32] 0 0
China
State/province [32] 0 0
Hangzhou
Country [33] 0 0
China
State/province [33] 0 0
Hengyang
Country [34] 0 0
China
State/province [34] 0 0
Jining
Country [35] 0 0
China
State/province [35] 0 0
Nanjing
Country [36] 0 0
China
State/province [36] 0 0
Shanghai
Country [37] 0 0
China
State/province [37] 0 0
Wenzhou
Country [38] 0 0
China
State/province [38] 0 0
Zhengzhou
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha 2
Country [40] 0 0
Denmark
State/province [40] 0 0
Aarhus N
Country [41] 0 0
Denmark
State/province [41] 0 0
Copenhagen
Country [42] 0 0
Denmark
State/province [42] 0 0
Odense C
Country [43] 0 0
France
State/province [43] 0 0
Angers
Country [44] 0 0
France
State/province [44] 0 0
Brest Cedex 2
Country [45] 0 0
France
State/province [45] 0 0
Le Mans Cedex
Country [46] 0 0
France
State/province [46] 0 0
Lille Cedex
Country [47] 0 0
France
State/province [47] 0 0
Paris Cedex 13
Country [48] 0 0
France
State/province [48] 0 0
Paris
Country [49] 0 0
France
State/province [49] 0 0
Reims
Country [50] 0 0
France
State/province [50] 0 0
Rouen
Country [51] 0 0
France
State/province [51] 0 0
Strasbourg
Country [52] 0 0
France
State/province [52] 0 0
Toulouse
Country [53] 0 0
Germany
State/province [53] 0 0
Bad Nauheim
Country [54] 0 0
Germany
State/province [54] 0 0
Berlin
Country [55] 0 0
Germany
State/province [55] 0 0
Herne
Country [56] 0 0
Germany
State/province [56] 0 0
München
Country [57] 0 0
Germany
State/province [57] 0 0
Tübingen
Country [58] 0 0
Hungary
State/province [58] 0 0
Debrecen
Country [59] 0 0
Hungary
State/province [59] 0 0
Szeged
Country [60] 0 0
India
State/province [60] 0 0
Ahmedabad
Country [61] 0 0
India
State/province [61] 0 0
Dehradun
Country [62] 0 0
India
State/province [62] 0 0
Gurugram
Country [63] 0 0
India
State/province [63] 0 0
Hyderabad
Country [64] 0 0
India
State/province [64] 0 0
Kolkata
Country [65] 0 0
India
State/province [65] 0 0
Mumbai
Country [66] 0 0
India
State/province [66] 0 0
Mysuru
Country [67] 0 0
India
State/province [67] 0 0
New Delhi
Country [68] 0 0
India
State/province [68] 0 0
Puducherry
Country [69] 0 0
India
State/province [69] 0 0
Secunderabad
Country [70] 0 0
Israel
State/province [70] 0 0
Afula
Country [71] 0 0
Israel
State/province [71] 0 0
Haifa
Country [72] 0 0
Israel
State/province [72] 0 0
Jerusalem
Country [73] 0 0
Israel
State/province [73] 0 0
Kfar Saba
Country [74] 0 0
Israel
State/province [74] 0 0
Ramat Gan
Country [75] 0 0
Italy
State/province [75] 0 0
Ancona
Country [76] 0 0
Italy
State/province [76] 0 0
Bari
Country [77] 0 0
Italy
State/province [77] 0 0
Catania
Country [78] 0 0
Italy
State/province [78] 0 0
Milano
Country [79] 0 0
Italy
State/province [79] 0 0
Padova
Country [80] 0 0
Italy
State/province [80] 0 0
Palermo
Country [81] 0 0
Italy
State/province [81] 0 0
Pavia
Country [82] 0 0
Italy
State/province [82] 0 0
Pisa
Country [83] 0 0
Italy
State/province [83] 0 0
Roma
Country [84] 0 0
Japan
State/province [84] 0 0
Asahikawa-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Bunkyo-ku
Country [86] 0 0
Japan
State/province [86] 0 0
Chiba-shi
Country [87] 0 0
Japan
State/province [87] 0 0
Fukuoka-shi
Country [88] 0 0
Japan
State/province [88] 0 0
Iruma-Gun
Country [89] 0 0
Japan
State/province [89] 0 0
Kawachinagano-shi
Country [90] 0 0
Japan
State/province [90] 0 0
Kawasaki-shi
Country [91] 0 0
Japan
State/province [91] 0 0
Nagoya-shi
Country [92] 0 0
Japan
State/province [92] 0 0
Omura-shi
Country [93] 0 0
Japan
State/province [93] 0 0
Sendai-shi
Country [94] 0 0
Japan
State/province [94] 0 0
Shinjuku-ku
Country [95] 0 0
Japan
State/province [95] 0 0
Tachikawa-shi
Country [96] 0 0
Japan
State/province [96] 0 0
Yotsukaido-shi
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Daejeon
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Seoul
Country [99] 0 0
Mexico
State/province [99] 0 0
Ciudad de Mexico
Country [100] 0 0
Mexico
State/province [100] 0 0
Culiacan
Country [101] 0 0
Mexico
State/province [101] 0 0
D.F
Country [102] 0 0
Mexico
State/province [102] 0 0
Guadalajara
Country [103] 0 0
Mexico
State/province [103] 0 0
Mexico City
Country [104] 0 0
Mexico
State/province [104] 0 0
Mexico
Country [105] 0 0
Netherlands
State/province [105] 0 0
Amsterdam
Country [106] 0 0
Poland
State/province [106] 0 0
Bialystok
Country [107] 0 0
Poland
State/province [107] 0 0
Kraków
Country [108] 0 0
Poland
State/province [108] 0 0
Poznan
Country [109] 0 0
Poland
State/province [109] 0 0
Warszawa
Country [110] 0 0
Poland
State/province [110] 0 0
Lódz
Country [111] 0 0
Spain
State/province [111] 0 0
Barcelona
Country [112] 0 0
Spain
State/province [112] 0 0
Cordoba
Country [113] 0 0
Spain
State/province [113] 0 0
L'Hospitalet de Llobregat
Country [114] 0 0
Spain
State/province [114] 0 0
La Coruña
Country [115] 0 0
Spain
State/province [115] 0 0
Madrid
Country [116] 0 0
Spain
State/province [116] 0 0
Sabadell
Country [117] 0 0
Spain
State/province [117] 0 0
Valladolid
Country [118] 0 0
Sweden
State/province [118] 0 0
Stockholm
Country [119] 0 0
Sweden
State/province [119] 0 0
Uppsala
Country [120] 0 0
Taiwan
State/province [120] 0 0
Kaohsiung
Country [121] 0 0
Taiwan
State/province [121] 0 0
New Taipei
Country [122] 0 0
Taiwan
State/province [122] 0 0
Taichung
Country [123] 0 0
Taiwan
State/province [123] 0 0
Taipei
Country [124] 0 0
Taiwan
State/province [124] 0 0
Taoyuan
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Edinburgh
Country [126] 0 0
United Kingdom
State/province [126] 0 0
London
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Wolverhampton
Country [128] 0 0
Vietnam
State/province [128] 0 0
Ha Noi
Country [129] 0 0
Vietnam
State/province [129] 0 0
Hanoi
Country [130] 0 0
Vietnam
State/province [130] 0 0
Ho Chi Minh city
Country [131] 0 0
Vietnam
State/province [131] 0 0
Ho Chi Minh
Country [132] 0 0
Vietnam
State/province [132] 0 0
Hochiminh city

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment.
Trial website
https://clinicaltrials.gov/study/NCT06455449
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06455449